Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 20/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 20/20 | 0.43 |
| ▸ | NAE1 | Q13564 | 14/20 | 0.43 |
| ▸ | UBA3 | Q8TBC4 | 14/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17421728 | 1.00 | SAE1 (0.43) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17421707 | 1.00 | SAE1 (0.43) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17421670 | 0.94 | SAE1 (0.42) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17421688 | 0.94 | SAE1 (0.42) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL21800788 | 0.94 | SAE1 (0.42) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17429059 | 0.90 | SAE1 (0.45) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17421686 | 0.89 | SAE1 (0.47) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17421632 | 0.89 | SAE1 (0.47) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL28618416 | 0.89 | SAE1 (0.47) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL25394441 | 0.86 | SAE1 (0.44) | SAE1UBA2NAE1UBA3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-106999479-B | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | 米伦纽姆医药公司 | 2021-07-16 | — | — | CN | disclosed |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | SAE1, SUMO1, SUMO3 | SAE1 1/4885UBA2 5/4885NAE1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.